A Phase 2 interventional study of Romosozumab and Placebo in Fracture Healing, sponsored by Amgen. Completed at 103 sites in 23 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-09-22.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to investigate the effect of romosozumab compared with placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in the midsection of the shinbone).
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.
Drug: Placebo
Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
Biological: Romosozumab
Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
Biological: Romosozumab
Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.
Biological: Romosozumab
Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
Biological: Romosozumab
Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
Biological: Romosozumab
Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.
Biological: Romosozumab
Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
Biological: Romosozumab
Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
Biological: Romosozumab
Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.
Biological: Romosozumab
Administered by subcutaneous injection
Also known as: AMG 785, Evenity
Administered by subcutaneous injection
Time to Radiographic Healing
Time to radiographic healing was defined as the time from intramedullary (IM) nailing to the first occurrence of bridging of 3 out of 4 cortices. Radiographic fracture healing was determined by a panel of independent reviewers (orthopedic/trauma surgeons and radiologists) blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.
Time frame: 52 weeks
Change From Week 8 in Short Form (36) Health Survey Physical Functioning Domain
The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2, is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical functioning domain includes 10 questions that assess limitations in physical activities because of health problems. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. The range of SF-36 physical functioning is 14.94 - 57.03. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement in physical functioning.
Time frame: Week 8 and weeks 12, 16, 20, 24, 36, and 52
Number of Participants With Unplanned Revision Surgeries
Time frame: 52 weeks
Time to Clinical Healing
Time to clinical healing was defined as the time from the IM nailing surgery date to the first date that both the score for ability to bear weight on the fractured limb and the score for absence of pain at the fracture site were equal to 6. The score for the ability to bear weight on the fractured limb was based on the ability to stand on affected leg without assistive device and the ability to walk without assistive device. The score ranges from 0 (unable to bear full body weight on the fractured limb) to 6 (able to bear full body weight on the fractured limb). Absence of pain at the fracture site was based on the absence of pain at the fracture site when applying direct pressure to the fracture site and applying a stress to the fracture site. The score ranges from 0 (pain without palpation at fracture site) to 6 (total absence of pain at fracture site). Time to clinical healing was estimated using CIF; unplanned revision surgery was considered a competing risk in CIF estimate.
Time frame: 52 weeks
This study was conducted at 66 centers in Europe, India, North America, Australia, New Zealand, Hong Kong, and Mexico. Participants were enrolled from 02 September 2009 to 19 September 2011.
| Milestone | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 103 | 34 | 34 | 33 | 33 | 33 | 33 | 33 | 31 | 35 |
| Received treatment | 100 | 34 | 34 | 32 | 33 | 32 | 31 | 32 | 30 | 35 |
| Completed | 83 | 29 | 32 | 29 | 32 | 24 | 27 | 26 | 27 | 28 |
| Not completed | 20 | 5 | 2 | 4 | 1 | 9 | 6 | 7 | 4 | 7 |
| Withdrew: Ineligibility determined | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Noncompliance | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 7 | 2 | 1 | 1 | 1 | 5 | 3 | 2 | 4 | 2 |
| Withdrew: Lost to follow-up | 9 | 1 | 0 | 2 | 0 | 3 | 2 | 2 | 0 | 4 |
Time to radiographic healing was defined as the time from intramedullary (IM) nailing to the first occurrence of bridging of 3 out of 4 cortices. Radiographic fracture healing was determined by a panel of independent reviewers (orthopedic/trauma surgeons and radiologists) blinded to treatment. The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.
| weeks | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Radiographic Healing | 16.4 (14.6 to 18.0) | 18.6 (14.0 to 24.4) | 18.3 (13.0 to 21.0) | 18.2 (13.7 to 20.7) | 17.8 (12.6 to 22.9) | 18.1 (13.1 to 20.7) | 17.0 (12.7 to 21.4) | 14.4 (12.6 to 17.0) | 15.4 (13.3 to 17.4) | 16.4 (14.4 to 18.6) |
The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2, is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical functioning domain includes 10 questions that assess limitations in physical activities because of health problems. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. The range of SF-36 physical functioning is 14.94 - 57.03. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement in physical functioning.
| units on a scale | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses |
|---|---|---|---|---|---|---|---|---|---|---|
| Week 12 | 5.77 ± 9.90 | 6.31 ± 6.84 | 5.67 ± 8.60 | 5.04 ± 9.01 | 4.28 ± 8.22 | 7.08 ± 8.06 | 3.63 ± 9.30 | 3.65 ± 9.06 | 7.33 ± 7.99 | 5.64 ± 6.67 |
| Week 16 | 9.64 ± 10.36 | 9.83 ± 7.24 | 9.19 ± 11.30 | 9.28 ± 11.14 | 8.89 ± 10.71 | 11.18 ± 9.23 | 8.78 ± 11.34 | 9.23 ± 9.59 | 9.50 ± 9.01 | 9.01 ± 10.41 |
| Week 20 | 13.20 ± 12.25 | 14.53 ± 9.69 | 10.45 ± 11.66 | 13.50 ± 12.02 | 12.13 ± 10.88 | 14.77 ± 13.52 | 12.44 ± 11.97 | 12.61 ± 10.88 | 12.50 ± 10.76 | 11.05 ± 11.56 |
| Week 24 | 15.87 ± 11.55 | 15.07 ± 9.31 | 10.34 ± 13.31 | 15.90 ± 11.26 | 14.57 ± 10.34 | 16.84 ± 12.70 | 11.79 ± 17.64 | 13.05 ± 10.99 | 13.05 ± 10.25 | 12.38 ± 14.04 |
| Week 36 | 19.57 ± 11.60 | 20.96 ± 11.68 | 11.48 ± 17.84 | 17.23 ± 10.15 | 17.61 ± 11.03 | 19.43 ± 12.83 | 15.70 ± 19.03 | 15.01 ± 11.23 | 17.47 ± 14.34 | 15.22 ± 15.20 |
| Week 52 | 20.74 ± 11.96 | 23.47 ± 11.55 | 13.63 ± 19.04 | 19.02 ± 10.80 | 19.63 ± 12.17 | 24.80 ± 11.24 | 17.19 ± 15.51 | 15.50 ± 13.17 | 18.29 ± 14.94 | 15.44 ± 17.15 |
| Participants | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Unplanned Revision Surgeries | 8 | 1 | 3 | 3 | 1 | 0 | 0 | 0 | 1 | 1 |
Time to clinical healing was defined as the time from the IM nailing surgery date to the first date that both the score for ability to bear weight on the fractured limb and the score for absence of pain at the fracture site were equal to 6. The score for the ability to bear weight on the fractured limb was based on the ability to stand on affected leg without assistive device and the ability to walk without assistive device. The score ranges from 0 (unable to bear full body weight on the fractured limb) to 6 (able to bear full body weight on the fractured limb). Absence of pain at the fracture site was based on the absence of pain at the fracture site when applying direct pressure to the fracture site and applying a stress to the fracture site. The score ranges from 0 (pain without palpation at fracture site) to 6 (total absence of pain at fracture site). Time to clinical healing was estimated using CIF; unplanned revision surgery was considered a competing risk in CIF estimate.
| weeks | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Clinical Healing | 18.4 (16.6 to 20.4) | 21.4 (15.7 to 28.6) | 18.3 (14.4 to 22.4) | 17.1 (14.4 to 21.0) | 20.8 (12.6 to 28.0) | 22.3 (15.0 to 24.3) | 15.0 (12.6 to 17.0) | 16.3 (12.4 to 21.0) | 14.6 (12.9 to 18.6) | 17.6 (14.9 to 19.7) |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 10/100 (10%) | 38/100 (38%) |
| Romosozumab 70 mg: 2 Doses | — | 4/34 (11.8%) | 9/34 (26.5%) |
| Romosozumab 70 mg: 3 Doses | — | 2/34 (5.9%) | 17/34 (50%) |
| Romosozumab 70 mg: 4 Doses | — | 3/32 (9.4%) | 12/32 (37.5%) |
| Romosozumab 140 mg: 2 Doses | — | 3/33 (9.1%) | 16/33 (48.5%) |
| Romosozumab 140 mg: 3 Doses | — | 4/32 (12.5%) | 7/32 (21.9%) |
| Romosozumab 140 mg: 4 Doses | — | 2/31 (6.5%) | 9/31 (29%) |
| Romosozumab 210 mg: 2 Doses | — | 3/32 (9.4%) | 10/32 (31.3%) |
| Romosozumab 210 mg: 3 Doses | — | 3/30 (10%) | 9/30 (30%) |
| Romosozumab 210 mg: 4 Doses | — | 0/35 (0%) | 6/35 (17.1%) |
| Event | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses |
|---|---|---|---|---|---|---|---|---|---|---|
| Device related infectionInfections and infestations | 1/100 | 0/34 | 0/34 | 0/32 | 0/33 | 0/32 | 0/31 | 0/32 | 1/30 | 0/35 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 0/32 | 0/31 | 0/32 | 1/30 | 0/35 |
| Calculus uretericRenal and urinary disorders | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 0/32 | 0/31 | 0/32 | 1/30 | 0/35 |
| Wound infectionInfections and infestations | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 1/32 | 1/31 | 0/32 | 0/30 | 0/35 |
| Transient ischaemic attackNervous system disorders | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 0/32 | 1/31 | 0/32 | 0/30 | 0/35 |
| InfectionInfections and infestations | 0/100 | 0/34 | 1/34 | 0/32 | 0/33 | 1/32 | 0/31 | 0/32 | 0/30 | 0/35 |
| MalariaInfections and infestations | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 1/32 | 0/31 | 0/32 | 0/30 | 0/35 |
| Femur fractureInjury, poisoning and procedural complications | 1/100 | 0/34 | 0/34 | 0/32 | 0/33 | 1/32 | 0/31 | 0/32 | 0/30 | 0/35 |
| Fracture displacementInjury, poisoning and procedural complications | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 0/32 | 0/31 | 1/32 | 0/30 | 0/35 |
| ExostosisMusculoskeletal and connective tissue disorders | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 0/32 | 0/31 | 1/32 | 0/30 | 0/35 |
| Event | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses |
|---|---|---|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/100 | 1/34 | 1/34 | 5/32 | 4/33 | 3/32 | 0/31 | 4/32 | 2/30 | 2/35 |
| Oedema peripheralGeneral disorders | 6/100 | 0/34 | 4/34 | 4/32 | 3/33 | 2/32 | 1/31 | 3/32 | 2/30 | 1/35 |
| Upper respiratory tract infectionInfections and infestations | 3/100 | 1/34 | 4/34 | 0/32 | 0/33 | 1/32 | 0/31 | 1/32 | 0/30 | 0/35 |
| DiarrhoeaGastrointestinal disorders | 2/100 | 0/34 | 2/34 | 0/32 | 2/33 | 0/32 | 0/31 | 1/32 | 3/30 | 0/35 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/100 | 0/34 | 0/34 | 0/32 | 1/33 | 2/32 | 3/31 | 1/32 | 1/30 | 0/35 |
| Bone painMusculoskeletal and connective tissue disorders | 3/100 | 1/34 | 0/34 | 3/32 | 1/33 | 1/32 | 0/31 | 0/32 | 2/30 | 0/35 |
| PainGeneral disorders | 7/100 | 0/34 | 2/34 | 1/32 | 1/33 | 1/32 | 1/31 | 0/32 | 0/30 | 1/35 |
| VomitingGastrointestinal disorders | 4/100 | 0/34 | 1/34 | 0/32 | 0/33 | 0/32 | 0/31 | 0/32 | 2/30 | 0/35 |
| FallInjury, poisoning and procedural complications | 3/100 | 0/34 | 0/34 | 1/32 | 1/33 | 1/32 | 0/31 | 0/32 | 2/30 | 0/35 |
| Limb injuryInjury, poisoning and procedural complications | 0/100 | 0/34 | 0/34 | 0/32 | 0/33 | 0/32 | 0/31 | 0/32 | 2/30 | 0/35 |
| Age, Continuous(years) | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 40.3 ± 13.8 | 38.6 ± 13.8 | 43.2 ± 17.7 | 45.9 ± 15.6 | 41.3 ± 13.7 | 41.0 ± 14.9 | 38.7 ± 12.7 | 42.8 ± 13.7 | 36.8 ± 13.8 | 41.7 ± 14.4 | 40.9 ± 14.4 |
| Sex: Female, Male(Participants) | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 29 | 7 | 10 | 8 | 8 | 11 | 11 | 5 | 13 | 12 | 114 |
| Male | 74 | 27 | 24 | 25 | 25 | 22 | 22 | 28 | 18 | 23 | 288 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 80 | 20 | 24 | 29 | 22 | 23 | 24 | 25 | 24 | 28 | 299 |
| Black or African American | 2 | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 8 |
| Hispanic or Latino | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Asian | 20 | 11 | 9 | 3 | 9 | 8 | 8 | 7 | 6 | 5 | 86 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Randomization Stratification(Participants) | Placebo | Romosozumab 70 mg: 2 Doses | Romosozumab 70 mg: 3 Doses | Romosozumab 70 mg: 4 Doses | Romosozumab 140 mg: 2 Doses | Romosozumab 140 mg: 3 Doses | Romosozumab 140 mg: 4 Doses | Romosozumab 210 mg: 2 Doses | Romosozumab 210 mg: 3 Doses | Romosozumab 210 mg: 4 Doses | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Closed with reamed IM nail | 88 | 30 | 30 | 29 | 29 | 29 | 29 | 29 | 28 | 29 | 350 |
| Gustilo type I/II open with reamed IM nail | 10 | 3 | 4 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 42 |
| Gustilo type I/II open with unreamed IM nail | 5 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 10 |
Showing the first 100 of 103 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Sep 2009 to primary completion in Mar 2012, 30 months.
Results were first posted in May 2019, 7 years 1 month after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab